Physician profile
Mark D Horowitz
NPI 1154490530
$7,944.91
in general payments reported to CMS, 2019-2025
30 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $438 · 2021: $1,172 · 2022: $1,337 · 2023: $1,101 · 2024: $1,482 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,782 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,781.97 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,980.02 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $1,477.31 | 2019-2025 | Krystexxa, Otezla, Enbrel |
| Mallinckrodt Hospital Products INC. | $704.91 | 2020-2024 | Acthar |
| Palette Life Sciences, INC. | $447.98 | 2022 | |
| Pfizer INC. | $445.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $399.77 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $399.04 | 2022-2025 | Saphnelo, Airsupra, Breztri |
| Lilly USA, LLC | $350.57 | 2019-2025 | Mounjaro, Taltz, Zepbound |
| Hikma Pharmaceuticals USA | $268.42 | 2019-2023 | Mitigare |
| Novartis Pharmaceuticals Corporation | $187.13 | 2023-2025 | |
| Gilead Sciences, INC. | $149.90 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $139.62 | 2019 | |
| Alexion Pharmaceuticals, INC. | $134.55 | 2024 | |
| Abbvie INC. | $123.54 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $107.74 | 2019-2025 | Orencia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $105.19 | 2024 | Arcalyst |
| Genzyme Corporation | $94.92 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $53.92 | 2024-2025 | Sovuna, Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $52.95 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $47.23 | 2021 | |
| Scilex Pharmaceuticals INC. | $46.86 | 2024 | |
| Eyevance Pharmaceuticals LLC | $44.58 | 2021 | |
| Depuy Synthes Sales INC. | $39.91 | 2019-2023 | Orthovisc |
| Leo Pharma INC. | $31.28 | 2019 | |
| Ucb, INC. | $25.26 | 2019 | |
| Celgene Corporation | $23.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.50 | 2023 | Entyvio |
| Kowa Pharmaceuticals America, INC. | $16.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.94 | 2019 | |
| Avion Pharmaceuticals | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.